These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34023874)

  • 1. Clarifying the Trade-Offs of Risk-Stratified Screening for Prostate Cancer: A Cost-Effectiveness Study.
    Hendrix N; Gulati R; Jiao B; Kader AK; Ryan ST; Etzioni R
    Am J Epidemiol; 2021 Oct; 190(10):2064-2074. PubMed ID: 34023874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
    J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
    PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
    Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
    Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
    PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History.
    Cenin DR; Naber SK; de Weerdt AC; Jenkins MA; Preen DB; Ee HC; O'Leary PC; Lansdorp-Vogelaar I
    Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):10-21. PubMed ID: 31748260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates.
    Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K
    Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness Analysis of Prostate-Specific Antigen Screening Among Chinese Men.
    Zhao G; Shao Y; Zhang N; Wang J; Yuan L; Sun X; Shi L
    Value Health Reg Issues; 2020 May; 21():272-279. PubMed ID: 32402819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea.
    Shin S; Kim YH; Hwang JS; Lee YJ; Lee SM; Ahn J
    Asian Pac J Cancer Prev; 2014; 15(8):3383-9. PubMed ID: 24870726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of screening strategies for Lynch syndrome.
    Barzi A; Sadeghi S; Kattan MW; Meropol NJ
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25794514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of a genetic test for breast cancer risk.
    Folse HJ; Green LE; Kress A; Allman R; Dinh TA
    Cancer Prev Res (Phila); 2013 Dec; 6(12):1328-36. PubMed ID: 24309564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
    Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
    BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of Prostate Health Index for prostate cancer detection.
    Nichol MB; Wu J; Huang J; Denham D; Frencher SK; Jacobsen SJ
    BJU Int; 2012 Aug; 110(3):353-62. PubMed ID: 22077934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of harms, benefits, and cost-effectiveness of prostate cancer screening: A micro-simulation study of 230 scenarios.
    Getaneh AM; Heijnsdijk EAM; Roobol MJ; de Koning HJ
    Cancer Med; 2020 Oct; 9(20):7742-7750. PubMed ID: 32813910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.
    de Carvalho TM; Heijnsdijk EAM; de Koning HJ
    Cancer; 2018 Feb; 124(3):507-513. PubMed ID: 29231973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.